Search for: "Biogen Idec, Inc."
Results 81 - 100
of 113
Sort by Relevance
|
Sort by Date
23 Jun 2010, 8:00 am
Biogen IDEC Inc., 537 F.3d 35, 48 (1st Cir. 2008). [read post]
10 Jun 2010, 3:58 am
(Patent Docs) Avonex (Interferon) – US: Biogen launches submarine patent against competing providers of Interferon-Beta products: Biogen Idec MA Inc. v. [read post]
24 May 2010, 9:11 am
Brooks OfficeMax Inc. [read post]
28 Mar 2010, 8:33 pm
Biogen Idec, Inc. et al. v. [read post]
27 Feb 2010, 3:23 pm
Biogen Idec presaged how arbitrary the Bilski test can be when applied to such drug/medical dosage calibration techniques. [read post]
7 Jan 2010, 10:56 am
Biogen Idec Inc (BIIB.O) said on Wednesday that four more patients taking its multiple sclerosis drug Tysabri had developed a potentially deadly brain infection known as PML in November, bringing the total to 28. [read post]
29 Dec 2009, 9:09 pm
Miller, Vice President of Corporate Business Development, Eli Lilly Reid Leonard, Vice President External Licensing and Business Development, Merck Jules Musling, VP, Johnson & Johnson Carlos Garrido, Finance Director , Head of Strategic Planning and Business Development South America, AstraZeneca Peter Verheyen, VP Business Development, Johnson & Johnson Michael Lytton, EVP Business Development, Biogen Idec Inc Mark Dennish, Vice President, Business Development,… [read post]
29 Dec 2009, 9:09 pm
Miller, Vice President of Corporate Business Development, Eli Lilly Reid Leonard, Vice President External Licensing and Business Development, Merck Jules Musling, VP, Johnson & Johnson Carlos Garrido, Finance Director , Head of Strategic Planning and Business Development South America, AstraZeneca Peter Verheyen, VP Business Development, Johnson & Johnson Michael Lytton, EVP Business Development, Biogen Idec Inc Mark Dennish, Vice President, Business Development,… [read post]
8 Oct 2009, 6:05 am
Teva Pharmaceuticals USA, Inc (Patent Docs) (Patent Baristas) (GenericsWeb) General Biotech legislative agenda: healthcare, energy, patents and capital (IP Watch) India: Applying for patents does pay: Wockhardt wins kudos from the Indian government (SPICY IP) US: CAFC ruling in Board of Trustees of the Leland Stanford Junior University et al v Roche Molecular Systems et al - How to lose a patent? [read post]
23 Sep 2009, 7:03 am
" Like all drugs, Tysabri, which is marketed by Biogen Idec Inc. and Elan Corp. [read post]
16 Sep 2009, 9:59 pm
Biogen Idec, combined with Justice Breyer's dissent in Laboratory Corp. v. [read post]
9 Aug 2009, 12:44 am
Biogen IDEC, 304 F.App'x 866 (Fed. [read post]
23 Jun 2009, 7:15 am
Biogen Idec Inc., the maker of Tysabri, reported the case on Friday, one week after the eighth case was reported. [read post]
28 May 2009, 9:59 pm
Noonan -- Last week, Biogen Idec sponsored a "Super Session" at the BIO 2009 International Conference entitled "Weathering the Perfect Storm of Financial Distress and Political Pressure. [read post]
24 May 2009, 10:58 pm
In the case IN RE GENENTECH, INC. and BIOGEN IDEC INC., the petitioners sought, and obtained, a writ of mandamus to move the patent case from ED Texas to ND California. [read post]
8 May 2009, 8:00 am
(Property intangible) US: Supreme Court rules 9-0 that CAFC has jurisdiction to review case remanded by district court to state court: Carlsbad Technology Inc v HIF Bio, Inc et al (Managing Intellectual Property) (Patently-O) US: Anticipation by a laundry list of prophetic DNA sequences: In re Gleave (Holman's Biotech IP Blog) US: Reverse payment settlements and biotechnology (Holman's Biotech IP Blog) US: Biogen seeks review and correction of patent term… [read post]
21 Apr 2009, 2:20 pm
We get some insightful additional information from a Dow Jones article, "Biogen Says Sixth MS Patient On Tysabri Gets Brain Infection": Tysabri - sold by the Cambridge, Mass., biotech [Biogen Idec Inc. [read post]
8 Apr 2009, 11:47 am
There will be a phased voluntary withdrawal of psoriasis drug Raptiva from the U.S. market due to its link to a brain infection.Raptiva has recently been associated with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system.Authorities in Europe, where Raptiva is sold by Merck KGaA (MRCG.DE), recommended in February that the drug be suspended in light of the PML risk.The European Commission is expected to follow that… [read post]
22 Dec 2008, 11:28 pm
By Kevin E. [read post]
19 Dec 2008, 9:20 pm
Biogen IDEC. [read post]
